Published in Retrovirology on October 11, 2010
Immune Responses to Two Experimental HIV Vaccines in Healthy Adults | NCT01386489
SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature (2011) 9.30
Disparate associations of HLA class I markers with HIV-1 acquisition and control of viremia in an African population. PLoS One (2011) 1.01
Workshop summary: Novel biomarkers for HIV incidence assay development. AIDS Res Hum Retroviruses (2012) 0.95
Cell-to-cell transmission of retroviruses: Innate immunity and interferon-induced restriction factors. Virology (2011) 0.93
Association of chemokine receptor gene (CCR2-CCR5) haplotypes with acquisition and control of HIV-1 infection in Zambians. Retrovirology (2011) 0.93
Analysis of NKp30/NCR3 isoforms in untreated HIV-1-infected patients from the ANRS SEROCO cohort. Oncoimmunology (2013) 0.92
RIG-I activation inhibits HIV replication in macrophages. J Leukoc Biol (2013) 0.88
Unbiased proteomics analysis demonstrates significant variability in mucosal immune factor expression depending on the site and method of collection. PLoS One (2013) 0.86
Dynamics of innate immunity are key to chronic immune activation in AIDS. Curr Opin HIV AIDS (2012) 0.85
Circulating biomarkers of immune activation distinguish viral suppression from nonsuppression in HAART-treated patients with advanced HIV-1 subtype C infection. Mediators Inflamm (2014) 0.82
Early biodistribution and persistence of a protective live attenuated SIV vaccine elicits localised innate responses in multiple lymphoid tissues. PLoS One (2014) 0.82
Rational design of HIV vaccines and microbicides: report of the EUROPRISE network annual conference 2010. J Transl Med (2011) 0.82
Human beta-defensins 2 and -3 cointernalize with human immunodeficiency virus via heparan sulfate proteoglycans and reduce infectivity of intracellular virions in tonsil epithelial cells. Virology (2015) 0.80
Complement and HIV-I infection/HIV-associated neurocognitive disorders. J Neurovirol (2014) 0.80
Defective dendritic cell response to Toll-like receptor 7/8 agonists in perinatally HIV-infected children. Pathog Dis (2013) 0.78
RIG-I detects HIV-1 infection and mediates type I interferon response in human macrophages from patients with HIV-1-associated neurocognitive disorders. Genet Mol Res (2015) 0.76
Defining epitope coverage requirements for T cell-based HIV vaccines: theoretical considerations and practical applications. J Transl Med (2011) 0.76
Rational design of HIV vaccines and microbicides: report of the EUROPRISE annual conference 2011. J Transl Med (2012) 0.75
Cytokine cascade and networks among MSM HIV seroconverters: implications for early immunotherapy. Sci Rep (2016) 0.75
Highlights, predictions, and changes. Retrovirology (2012) 0.75
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med (2009) 28.62
Initial sequence of the chimpanzee genome and comparison with the human genome. Nature (2005) 25.67
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A (2008) 16.54
Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature (2008) 14.99
Adaptive immune features of natural killer cells. Nature (2009) 8.46
Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis (2006) 7.98
Fc receptor but not complement binding is important in antibody protection against HIV. Nature (2007) 7.96
Beta-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. Science (1999) 7.86
Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet (2002) 7.58
The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med (1990) 6.94
Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet (2007) 6.83
The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity (1999) 6.80
T cell- and B cell-independent adaptive immunity mediated by natural killer cells. Nat Immunol (2006) 6.23
Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis (2009) 6.17
HIV-1 accessory proteins--ensuring viral survival in a hostile environment. Cell Host Microbe (2008) 5.90
Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS (2003) 5.85
Semen-derived amyloid fibrils drastically enhance HIV infection. Cell (2007) 5.23
Glycerol monolaurate prevents mucosal SIV transmission. Nature (2009) 5.02
Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions. J Clin Invest (2005) 5.00
Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections. Nat Med (2008) 4.55
Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1. Nat Med (2009) 4.22
Langerin is a natural barrier to HIV-1 transmission by Langerhans cells. Nat Med (2007) 4.20
An interferon-alpha-induced tethering mechanism inhibits HIV-1 and Ebola virus particle release but is counteracted by the HIV-1 Vpu protein. Cell Host Microbe (2007) 4.17
The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? J Exp Med (2008) 4.15
Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes. J Exp Med (2007) 4.14
Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response. J Clin Invest (2009) 3.89
Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. PLoS One (2008) 3.85
Cytokine-induced memory-like natural killer cells. Proc Natl Acad Sci U S A (2009) 3.74
Global genomic analysis reveals rapid control of a robust innate response in SIV-infected sooty mangabeys. J Clin Invest (2009) 3.55
Human immunodeficiency virus type 1 activates plasmacytoid dendritic cells and concomitantly induces the bystander maturation of myeloid dendritic cells. J Virol (2004) 3.12
Antiinflammatory profiles during primary SIV infection in African green monkeys are associated with protection against AIDS. J Clin Invest (2005) 3.08
Interleukin-22-producing natural killer cells and lymphoid tissue inducer-like cells in mucosal immunity. Immunity (2009) 3.02
Epithelial cells trigger frontline immunoglobulin class switching through a pathway regulated by the inhibitor SLPI. Nat Immunol (2007) 2.96
Induction of APOBEC3 family proteins, a defensive maneuver underlying interferon-induced anti-HIV-1 activity. J Exp Med (2006) 2.83
MyD88-dependent immune activation mediated by human immunodeficiency virus type 1-encoded Toll-like receptor ligands. J Virol (2007) 2.77
Triggering TLR7 in mice induces immune activation and lymphoid system disruption, resembling HIV-mediated pathology. Blood (2008) 2.65
HIV inhibits CD4+ T-cell proliferation by inducing indoleamine 2,3-dioxygenase in plasmacytoid dendritic cells. Blood (2006) 2.58
Human epithelial beta-defensins 2 and 3 inhibit HIV-1 replication. AIDS (2003) 2.55
The control of viral infection by tripartite motif proteins and cyclophilin A. Retrovirology (2007) 2.54
DNA deamination in immunity: AID in the context of its APOBEC relatives. Adv Immunol (2007) 2.53
Monocyte-chemotactic activity of defensins from human neutrophils. J Clin Invest (1989) 2.50
Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate. J Immunol (2007) 2.47
Activation of the lectin DC-SIGN induces an immature dendritic cell phenotype triggering Rho-GTPase activity required for HIV-1 replication. Nat Immunol (2007) 2.43
APOBEC proteins and intrinsic resistance to HIV-1 infection. Philos Trans R Soc Lond B Biol Sci (2009) 2.40
Early resolution of acute immune activation and induction of PD-1 in SIV-infected sooty mangabeys distinguishes nonpathogenic from pathogenic infection in rhesus macaques. J Immunol (2008) 2.39
The cationic properties of SEVI underlie its ability to enhance human immunodeficiency virus infection. J Virol (2008) 2.38
HIV-1-infected monocyte-derived dendritic cells do not undergo maturation but can elicit IL-10 production and T cell regulation. Proc Natl Acad Sci U S A (2004) 2.38
Human neutrophil defensins selectively chemoattract naive T and immature dendritic cells. J Leukoc Biol (2000) 2.32
Reduced blood CD123+ (lymphoid) and CD11c+ (myeloid) dendritic cell numbers in primary HIV-1 infection. Blood (2001) 2.16
Human -defensin-3 activates professional antigen-presenting cells via Toll-like receptors 1 and 2. Proc Natl Acad Sci U S A (2007) 2.10
KIR/HLA pleiotropism: protection against both HIV and opportunistic infections. PLoS Pathog (2006) 2.06
HIV-activated human plasmacytoid DCs induce Tregs through an indoleamine 2,3-dioxygenase-dependent mechanism. J Clin Invest (2008) 2.06
Secretory leukocyte protease inhibitor binds to annexin II, a cofactor for macrophage HIV-1 infection. J Exp Med (2004) 2.05
Myeloid and plasmacytoid dendritic cells transfer HIV-1 preferentially to antigen-specific CD4+ T cells. J Exp Med (2005) 2.04
HLA class I subtype-dependent expansion of KIR3DS1+ and KIR3DL1+ NK cells during acute human immunodeficiency virus type 1 infection. J Virol (2009) 2.03
Carbohydrate-specific signaling through the DC-SIGN signalosome tailors immunity to Mycobacterium tuberculosis, HIV-1 and Helicobacter pylori. Nat Immunol (2009) 2.00
Primary infection with simian immunodeficiency virus: plasmacytoid dendritic cell homing to lymph nodes, type I interferon, and immune suppression. Blood (2008) 1.99
Transcriptional profiling in pathogenic and non-pathogenic SIV infections reveals significant distinctions in kinetics and tissue compartmentalization. PLoS Pathog (2009) 1.99
Regulation of TNF-related apoptosis-inducing ligand on primary CD4+ T cells by HIV-1: role of type I IFN-producing plasmacytoid dendritic cells. Proc Natl Acad Sci U S A (2005) 1.97
Cutting edge: increased NK cell activity in HIV-1-exposed but uninfected Vietnamese intravascular drug users. J Immunol (2003) 1.96
Human immunodeficiency virus, restriction factors, and interferon. J Interferon Cytokine Res (2009) 1.94
Evolution of innate and adaptive effector cell functions during acute HIV-1 infection. J Infect Dis (2007) 1.91
HIV-1 exploits innate signaling by TLR8 and DC-SIGN for productive infection of dendritic cells. Nat Immunol (2010) 1.90
Alpha interferon potently enhances the anti-human immunodeficiency virus type 1 activity of APOBEC3G in resting primary CD4 T cells. J Virol (2006) 1.84
Human alpha- and beta-interferon but not gamma- suppress the in vitro replication of LAV, HTLV-III, and ARV-2. J Interferon Res (1986) 1.83
APOBEC3G/3F mediates intrinsic resistance of monocyte-derived dendritic cells to HIV-1 infection. J Exp Med (2006) 1.82
Human beta-defensins suppress human immunodeficiency virus infection: potential role in mucosal protection. J Virol (2005) 1.75
Distinctive NK-cell receptor repertoires sustain high-level constitutive NK-cell activation in HIV-exposed uninfected individuals. Blood (2007) 1.72
Semen-mediated enhancement of HIV infection is donor-dependent and correlates with the levels of SEVI. Retrovirology (2010) 1.70
Accumulation of DC-SIGN+CD40+ dendritic cells with reduced CD80 and CD86 expression in lymphoid tissue during acute HIV-1 infection. AIDS (2002) 1.67
Rapid influx and death of plasmacytoid dendritic cells in lymph nodes mediate depletion in acute simian immunodeficiency virus infection. PLoS Pathog (2009) 1.66
Levels of innate immune factors in genital fluids: association of alpha defensins and LL-37 with genital infections and increased HIV acquisition. AIDS (2009) 1.64
Increased proportion of KIR3DS1 homozygotes in HIV-exposed uninfected individuals. AIDS (2008) 1.63
Plasmacytoid dendritic cell dynamics and alpha interferon production during Simian immunodeficiency virus infection with a nonpathogenic outcome. J Virol (2008) 1.62
Cell culture-produced hepatitis C virus impairs plasmacytoid dendritic cell function. Hepatology (2008) 1.57
Theta-defensins prevent HIV-1 Env-mediated fusion by binding gp41 and blocking 6-helix bundle formation. J Biol Chem (2006) 1.54
A retrovirus restriction factor TRIM5alpha is transcriptionally regulated by interferons. Biochem Biophys Res Commun (2005) 1.54
Syndecan-3 is a dendritic cell-specific attachment receptor for HIV-1. Proc Natl Acad Sci U S A (2007) 1.54
A selective defect of interferon alpha production in human immunodeficiency virus-infected monocytes. J Exp Med (1990) 1.53
Human immunodeficiency virus type 1 mediates global disruption of innate antiviral signaling and immune defenses within infected cells. J Virol (2009) 1.53
Is the high virulence of HIV-1 an unfortunate coincidence of primate lentiviral evolution? Nat Rev Microbiol (2009) 1.50
Alpha interferon enhances TRIM5alpha-mediated antiviral activities in human and rhesus monkey cells. J Virol (2007) 1.49
Activated CD34-derived Langerhans cells mediate transinfection with human immunodeficiency virus. J Virol (2007) 1.47
Killer immunoglobulin-like receptors and HLA act both independently and synergistically to modify HIV disease progression. Genes Immun (2005) 1.47
Dual role of alpha-defensin-1 in anti-HIV-1 innate immunity. J Clin Invest (2005) 1.47
Conferral of enhanced natural killer cell function by KIR3DS1 in early human immunodeficiency virus type 1 infection. J Virol (2008) 1.47
Regulation of HIV replication in infected monocytes by IFN-alpha. Mechanisms for viral restriction. J Immunol (1990) 1.44
Type I interferon as a link between innate and adaptive immunity through dendritic cell stimulation. Leuk Lymphoma (2004) 1.44
Multiple effects of interferon on the replication of human immunodeficiency virus type 1. Antiviral Res (1994) 1.42
HIV-1 infection of macrophages is dependent on evasion of innate immune cellular activation. AIDS (2009) 1.34
HIV protective KIR3DL1 and HLA-B genotypes influence NK cell function following stimulation with HLA-devoid cells. J Immunol (2010) 1.28
Biomarkers of cervicovaginal inflammation for the assessment of microbicide safety. Sex Transm Dis (2009) 1.25
A novel role for defensins in intestinal homeostasis: regulation of IL-1beta secretion. J Immunol (2007) 1.23
Decreased NK cell frequency and function is associated with increased risk of KIR3DL allele polymorphism in simian immunodeficiency virus-infected rhesus macaques with high viral loads. J Immunol (2009) 1.22
Elevated elafin/trappin-2 in the female genital tract is associated with protection against HIV acquisition. AIDS (2009) 1.21
Alpha-defensins block the early steps of HIV-1 infection: interference with the binding of gp120 to CD4. Blood (2007) 1.16
Novel innate immune functions of the whey acidic protein family. Trends Immunol (2008) 1.16
Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med (2003) 5.71
Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature (2005) 4.71
Presence of HIV-1 Gag-specific IFN-gamma+IL-2+ and CD28+IL-2+ CD4 T cell responses is associated with nonprogression in HIV-1 infection. J Immunol (2002) 2.95
Blockade of attachment and fusion receptors inhibits HIV-1 infection of human cervical tissue. J Exp Med (2004) 2.58
Target cells in vaginal HIV transmission. Microbes Infect (2003) 2.36
Cyanovirin-N inhibits AIDS virus infections in vaginal transmission models. AIDS Res Hum Retroviruses (2004) 2.22
Ex vivo culture of human colorectal tissue for the evaluation of candidate microbicides. AIDS (2006) 1.88
Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component. Proc Natl Acad Sci U S A (2009) 1.87
Candidate polyanion microbicides inhibit HIV-1 infection and dissemination pathways in human cervical explants. Retrovirology (2006) 1.58
Vaginal microbicides: moving ahead after an unexpected setback. AIDS (2007) 1.56
Which topical microbicides for blocking HIV-1 transmission will work in the real world? PLoS Med (2006) 1.56
Thymic stromal lymphopoietin (TSLP) acts as a potent mucosal adjuvant for HIV-1 gp140 vaccination in mice. Eur J Immunol (2011) 1.53
HIV-1 infection of human penile explant tissue and protection by candidate microbicides. AIDS (2009) 1.49
Granulocyte-macrophage colony-stimulating factor enhances viral load in human brain tissue: amelioration with stavudine. AIDS (2002) 1.44
Critical issues in mucosal immunity for HIV-1 vaccine development. J Allergy Clin Immunol (2008) 1.41
In vitro preclinical testing of nonoxynol-9 as potential anti-human immunodeficiency virus microbicide: a retrospective analysis of results from five laboratories. Antimicrob Agents Chemother (2006) 1.37
Selective transmission of R5 HIV-1 variants: where is the gatekeeper? J Transl Med (2011) 1.36
Cyanovirin-N potently inhibits human immunodeficiency virus type 1 infection in cellular and cervical explant models. J Gen Virol (2009) 1.28
Reverse transcriptase inhibitors as potential colorectal microbicides. Antimicrob Agents Chemother (2009) 1.26
Candidate microbicide PPCM blocks human immunodeficiency virus type 1 infection in cell and tissue cultures and prevents genital herpes in a murine model. J Virol (2008) 1.26
Multisite comparison of anti-human immunodeficiency virus microbicide activity in explant assays using a novel endpoint analysis. J Clin Microbiol (2009) 1.23
Sustained release of the CCR5 inhibitors CMPD167 and maraviroc from vaginal rings in rhesus macaques. Antimicrob Agents Chemother (2012) 1.23
HIV-1 pathogenesis differs in rectosigmoid and tonsillar tissues infected ex vivo with CCR5- and CXCR4-tropic HIV-1. AIDS (2007) 1.22
Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 agonist, promotes potent systemic and mucosal responses to intranasal immunization with HIVgp140. PLoS One (2012) 1.22
Molecular umbrellas: a novel class of candidate topical microbicides to prevent human immunodeficiency virus and herpes simplex virus infections. J Virol (2007) 1.19
Animal models for microbicide studies. Curr HIV Res (2012) 1.17
Novel innate immune functions of the whey acidic protein family. Trends Immunol (2008) 1.16
Phase I randomised clinical trial of an HIV-1(CN54), clade C, trimeric envelope vaccine candidate delivered vaginally. PLoS One (2011) 1.10
AIDS models: microbicides could learn from vaccines. Nat Med (2002) 1.06
Non-aqueous silicone elastomer gels as a vaginal microbicide delivery system for the HIV-1 entry inhibitor maraviroc. J Control Release (2011) 1.05
High-mannose-specific deglycosylation of HIV-1 gp120 induced by resistance to cyanovirin-N and the impact on antibody neutralization. Virology (2007) 1.05
Evaluation of TLR agonists as potential mucosal adjuvants for HIV gp140 and tetanus toxoid in mice. PLoS One (2012) 1.04
Vaccine adjuvants: a priority for vaccine research. Vaccine (2010) 1.03
Vaginal delivery of the recombinant HIV-1 clade-C trimeric gp140 envelope protein CN54gp140 within novel rheologically structured vehicles elicits specific immune responses. Vaccine (2009) 1.03
Antiviral breadth and combination potential of peptide triazole HIV-1 entry inhibitors. Antimicrob Agents Chemother (2011) 1.03
Colorectal microbicide design: triple combinations of reverse transcriptase inhibitors are optimal against HIV-1 in tissue explants. AIDS (2011) 1.01
Neutralizing IgG at the portal of infection mediates protection against vaginal simian/human immunodeficiency virus challenge. J Virol (2013) 1.01
Preclinical evaluation of lime juice as a topical microbicide candidate. Retrovirology (2008) 0.97
Role of capsule and interleukin-6 in long-term immune control of Cryptococcus neoformans infection by specifically activated human peripheral blood mononuclear cells. Infect Immun (2006) 0.95
Human immunodeficiency virus type 1 nucleocapsid inhibitors impede trans infection in cellular and explant models and protect nonhuman primates from infection. J Virol (2009) 0.95
Targeting of HIV-p24 particle-based vaccine into differential skin layers induces distinct arms of the immune responses. Vaccine (2011) 0.93
Highly conserved HIV-1 gp120 glycans proximal to CD4-binding region affect viral infectivity and neutralizing antibody induction. Virology (2011) 0.93
Restricted variable residues in the C-terminal segment of HIV-1 V3 loop regulate the molecular anatomy of CCR5 utilization. J Mol Biol (2005) 0.91
Transgenic plant production of Cyanovirin-N, an HIV microbicide. FASEB J (2005) 0.91
Assessment of mucosal immunity to HIV-1. Expert Rev Vaccines (2010) 0.91
Intravaginal immunization using the recombinant HIV-1 clade-C trimeric envelope glycoprotein CN54gp140 formulated within lyophilized solid dosage forms. Vaccine (2011) 0.90
PRO-2000, an antimicrobial gel for the potential prevention of HIV infection. Curr Opin Investig Drugs (2008) 0.90
Removal of two high-mannose N-linked glycans on gp120 renders human immunodeficiency virus 1 largely resistant to the carbohydrate-binding agent griffithsin. J Gen Virol (2011) 0.88
Saquinavir inhibits early events associated with establishment of HIV-1 infection: potential role for protease inhibitors in prevention. Antimicrob Agents Chemother (2012) 0.88
Mucosal application of gp140 encoding DNA polyplexes to different tissues results in altered immunological outcomes in mice. PLoS One (2013) 0.88
Preventing HIV-1 sexual transmission--not sexy enough science, or no benefit to the bottom line? J Antimicrob Chemother (2003) 0.88
Design, expression, and characterization of a multivalent, combination HIV microbicide. FASEB J (2009) 0.87
Herpes simplex virus type 2 infection of human epithelial cells induces CXCL9 expression and CD4+ T cell migration via activation of p38-CCAAT/enhancer-binding protein-β pathway. J Immunol (2012) 0.86
Preclinical evaluation of the HIV-1 fusion inhibitor L'644 as a potential candidate microbicide. Antimicrob Agents Chemother (2012) 0.86
A novel strategy for inducing enhanced mucosal HIV-1 antibody responses in an anti-inflammatory environment. PLoS One (2011) 0.85
Microneedle mediated intradermal delivery of adjuvanted recombinant HIV-1 CN54gp140 effectively primes mucosal boost inoculations. J Control Release (2012) 0.85
CCL19 and CCL28 augment mucosal and systemic immune responses to HIV-1 gp140 by mobilizing responsive immunocytes into secondary lymph nodes and mucosal tissue. J Immunol (2013) 0.85
A "prime-pull" vaccine strategy has a modest effect on local and systemic antibody responses to HIV gp140 in mice. PLoS One (2013) 0.85
C-C chemokine receptor type 5 (CCR5) utilization of transmitted and early founder human immunodeficiency virus type 1 envelopes and sensitivity to small-molecule CCR5 inhibitors. J Gen Virol (2010) 0.84
Evidence for Gag p24-specific CD4 T cells with reduced susceptibility to R5 HIV-1 infection in a UK cohort of HIV-exposed-seronegative subjects. AIDS (2003) 0.84
Mucosal tissue tropism and dissemination of HIV-1 subtype B acute envelope-expressing chimeric virus. J Virol (2012) 0.84
Pharmacokinetics of a CCR5 inhibitor in rhesus macaques following vaginal, rectal and oral application. J Antimicrob Chemother (2013) 0.83
Chemokine receptor expression and modulation by Mycobacterium tuberculosis antigens on mononuclear cells from human lymphoid tissues. Immunology (2006) 0.83
HIV-1 expressing the envelopes of transmitted/founder or control/reference viruses have similar infection patterns of CD4 T-cells in human cervical tissue ex vivo. PLoS One (2012) 0.82
Potential use of protease inhibitors as vaginal and colorectal microbicides. Curr HIV Res (2012) 0.81
Increased sensitivity of CD4+ T-effector cells to CD4+CD25+ Treg suppression compensates for reduced Treg number in asymptomatic HIV-1 infection. PLoS One (2010) 0.81
Pulmonary delivery of DNA vaccine constructs using deacylated PEI elicits immune responses and protects against viral challenge infection. J Control Release (2013) 0.81
Pertussis toxin and its binding unit inhibit HIV-1 infection of human cervical tissue and macrophages involving a CD14 pathway. J Infect Dis (2006) 0.80
Mycobacterium tuberculosis antigens specifically modulate CCR2 and MCP-1/CCL2 on lymphoid cells from human pulmonary hilar lymph nodes. J Immunol (2007) 0.79
Candidate microbicides and their mechanisms of action. Curr Top Microbiol Immunol (2014) 0.79
A comparative phase 1 clinical trial to identify anti-infective mechanisms of vitamin D in people with HIV infection. AIDS (2015) 0.79
Immunotherapy of prostate cancer: identification of new treatments and targets for therapy, and role of WAP domain-containing proteins. Biochem Soc Trans (2011) 0.78
Suppression of human immunodeficiency virus replication in human brain tissue by nucleoside reverse transcriptase inhibitors. J Neurovirol (2004) 0.77
Dynamic electrophoretic fingerprinting of the HIV-1 envelope glycoprotein. Retrovirology (2013) 0.77
Modified silicone elastomer vaginal gels for sustained release of antiretroviral HIV microbicides. J Pharm Sci (2014) 0.77
WFDC1/ps20: a host factor that influences the neutrophil response to murine hepatitis virus (MHV) 1 infection. Antiviral Res (2012) 0.76
Bifunctional CD4-DC-SIGN fusion proteins demonstrate enhanced avidity to gp120 and inhibit HIV-1 infection and dissemination. Antimicrob Agents Chemother (2012) 0.76
Whey acidic proteins (WAPs): novel modulators of innate immunity to HIV infection. Curr Opin HIV AIDS (2012) 0.76
Binding of HIV-1 virions to α4β 7 expressing cells and impact of antagonizing α4β 7 on HIV-1 infection of primary CD4+ T cells. Virol Sin (2014) 0.76
Vaginal microbicides: the importance of effective distribution, retention and coating of the mucosa. AIDS (2008) 0.75
Rational design of HIV vaccines and microbicides: report of the EUROPRISE annual conference 2011. J Transl Med (2012) 0.75
Molecular investigations into vaginal immunization with HIV gp41 antigenic construct H4A in a quick release solid dosage form. Vaccine (2012) 0.75
WFDC1 expression identifies memory CD4 T-lymphocytes rendered vulnerable to cell-cell HIV-1 transfer by promoting intercellular adhesive junctions. Retrovirology (2011) 0.75
Maraviroc and reverse transcriptase inhibitors combinations as potential preexposure prophylaxis candidates. AIDS (2016) 0.75
Elevated effector cell sensitivity to Treg-cell suppression that is not associated with reduced Th17-cell expression distinguishes HIV+ asymptomatic subjects from progressors. Eur J Immunol (2011) 0.75
Intracellular cytokines may model immunoregulation of abacavir hypersensitivity in HIV-infected subjects. J Allergy Clin Immunol (2005) 0.75
Therapeutic role of CD8+ T cells in HIV-1 infection: targets and suppressors of viral replication. Expert Opin Biol Ther (2005) 0.75
Chemokine/cytokine production by mononuclear cells from human lymphoid tissues and their modulation by Mycobacterium tuberculosis antigens. FEMS Immunol Med Microbiol (2007) 0.75